R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class ...

Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care; Partnership with Alebund Pharmaceuticals to gai ...

New AI solutions improve access and simplify the primary care experience for patientsSAN MATEO, Calif., 2026 /PRNewswire/ -- Marshall Health ...

In this week’s edition of InnovationRx, we look at Roche’s big AI drug development bet, an E. coli outbreak in raw milk ...

R1 plans to initiate a Phase IIb study of AP306 later this year.

Alongside R1 Therapeutics, Mestag Therapeutics and iDEL Therapeutics also brought in money on Tuesday, helping to push their ...

While giant fintechs like Stripe and Ramp garner nosebleed valuations, others struggle to raise funding or languish in the stock market.

The startup believes a pill it licensed from a Chinese biotech company could be more potent, and convenient to take, than existing treatments for a common complication of chronic kidney disease.

R1 Therapeutics said on Tuesday it had launched operations with a $77.5 million Series A funding round and an exclusive ...

This week, Cyclops announced an $8 million strategic investment from Castle Island Ventures, F-Prime and Shift4 Payments to build the stablecoin and crypto ...

A clinical-stage biotechnology company focused on developing therapies for kidney disease, with an initial emphasis on hyperphosphatemia in patients with chronic kidney disease (CKD). R1 Therapeutics ...